BioAdaptives, Inc.

AI-generated fair value estimate for this company.

Method: Net Asset Value / liquidation approach using Q1 FY2026 10-Q (period ended ~May 2026): total assets $135,949 minus total liabilities $2,272,091 (incl. $1,563,920 derivative liabilities and $424,211 convertible notes)

Reasoning: BDPT (BioAdaptives Inc) is a going-concern-doubt nano-cap OTC stock with only $5,514 of quarterly revenue (its first ever reported revenue), negative operating cash flow of -$84,839/quarter, and a stockholders' deficit of $2,136,142; DCF is not meaningful given no track record of positive free cash flow or credible growth trajectory, so a net-asset/liquidation approach is used, which floors common equity fundamental value at approximately $0 since liabilities exceed assets and shareholders have limited liability; the ~$23K market cap reflects speculative option value only, not fundamentals